UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 642

Sortiert nach

Give PrEP a chance: moving on from the “risk compensation” concept

Journal of the International AIDS Society, 2019-08, Vol.22 (S6), p.e25351-n/a

2019

Link zum Volltext

Verfügbarkeit prüfen

COVID‐19–Related IgA Vasculitis

Arthritis & rheumatology (Hoboken, N.J.), 2020-11, Vol.72 (11), p.1952-1953

2020

Link zum Volltext

Verfügbarkeit prüfen

SARS-CoV-2 induces human plasmacytoid predendritic cell diversification via UNC93B and IRAK4

The Journal of experimental medicine, 2021-04, Vol.218 (4)

2021

Link zum Volltext

Verfügbarkeit prüfen

Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023

HIV medicine, 2023-11, Vol.24 (11), p.1126-1136

2023

Link zum Volltext

Verfügbarkeit prüfen

PrEP in Europe – expectations, opportunities and barriers

Journal of the International AIDS Society, 2016-10, Vol.19 (7(Suppl 6)), p.21103-n/a

2016

Link zum Volltext

Verfügbarkeit prüfen

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial

The Lancet (British edition), 2011-07, Vol.378 (9787), p.238-246

2011

Link zum Volltext

Verfügbarkeit prüfen

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

The Lancet (British edition), 2012-06, Vol.379 (9835), p.2429-2438

2012

Link zum Volltext

Verfügbarkeit prüfen

Complement C5 inhibition in patients with COVID-19 - a promising target?

Haematologica (Roma), 2020-12, Vol.105 (12), p.2847-2850

2020

Link zum Volltext

Verfügbarkeit prüfen

Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study

The Lancet (British edition), 2015-03, Vol.385 (9973), p.1098-1106

2015

Link zum Volltext

Verfügbarkeit prüfen

Remdesivir in combination with dexamethasone for patients hospitalized with COVID-19: A retrospective multicenter study

PloS one, 2022-02, Vol.17 (2), p.e0262564-e0262564

2022

Link zum Volltext

Verfügbarkeit prüfen

Tenofovir-Related Nephrotoxicity in Human Immunodeficiency Virus-Infected Patients: Three Cases of Renal Failure, Fanconi Syndrome, and Nephrogenic Diabetes Insipidus

Clinical infectious diseases, 2003-04, Vol.36 (8), p.1070-1073

2003

Link zum Volltext

Verfügbarkeit prüfen

CD8 Encephalitis in HIV-Infected Patients Receiving cART: A Treatable Entity

Clinical infectious diseases, 2013-07, Vol.57 (1), p.101-108

2013

Link zum Volltext

Verfügbarkeit prüfen

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

The Lancet (British edition), 2008-08, Vol.372 (9639), p.646-655

2008

Link zum Volltext

Verfügbarkeit prüfen

Response to “On the risk of using raw regional data on new HIV infections in France” by Tassi et al

Journal of the International AIDS Society, 2024-01, Vol.27 (1), p.e26207-n/a

2024

Link zum Volltext

Verfügbarkeit prüfen

Sexual behaviour and STIs among MSM living with HIV in the PrEP era: the French ANRS PRIMO cohort study

Journal of the International AIDS Society, 2024-03, Vol.27 (3), p.e26226-n/a

2024

Link zum Volltext

Verfügbarkeit prüfen

Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study

The lancet HIV, 2015-04, Vol.2 (4), p.e127-e136

2015

Link zum Volltext

Verfügbarkeit prüfen

Spatio‐temporal changes in pre‐exposure prophylaxis uptake among MSM in mainland France between 2016 and 2021: a Bayesian small area approach with MSM population estimation

Journal of the International AIDS Society, 2023-05, Vol.26 (5), p.e26089-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Incidence, risk factors and outcome of multi-drug resistant Acinetobacter baumannii nosocomial infections during an outbreak in a burn unit

International journal of infectious diseases, 2019-02, Vol.79, p.179-184

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study

The Lancet infectious diseases, 2012, Vol.12 (1), p.27-35

2012

Link zum Volltext

Verfügbarkeit prüfen

Sensitivity of five rapid HIV tests on oral fluid or finger-stick whole blood: a real-time comparison in a healthcare setting

PloS one, 2010-07, Vol.5 (7), p.e11581-e11581

2010

Link zum Volltext

Verfügbarkeit prüfen

Injectable long acting antiretroviral for HIV treatment and prevention: perspectives of potential users

BMC infectious diseases, 2023-02, Vol.23 (1), p.98-98, Article 98

2023

Link zum Volltext

Verfügbarkeit prüfen

Hepatitis Rebound after Infection with Yellow Fever Virus

Emerging infectious diseases, 2019-06, Vol.25 (6), p.1248-1249

2019

Link zum Volltext

Verfügbarkeit prüfen

Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients

PloS one, 2012-05, Vol.7 (5), p.e36673-e36673

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 642

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(612)
Mit Volltextzugriff
(569)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

Give PrEP a chance: moving on from the “risk compensation” concept

COVID‐19–Related IgA Vasculitis

SARS-CoV-2 induces human plasmacytoid predendritic cell diversification via UNC93B and IRAK4

Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023

PrEP in Europe – expectations, opportunities and barriers

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

Complement C5 inhibition in patients with COVID-19 - a promising target?

Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study

Remdesivir in combination with dexamethasone for patients hospitalized with COVID-19: A retrospective multicenter study

Tenofovir-Related Nephrotoxicity in Human Immunodeficiency Virus-Infected Patients: Three Cases of Renal Failure, Fanconi Syndrome, and Nephrogenic Diabetes Insipidus

CD8 Encephalitis in HIV-Infected Patients Receiving cART: A Treatable Entity

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

Response to “On the risk of using raw regional data on new HIV infections in France” by Tassi et al

Sexual behaviour and STIs among MSM living with HIV in the PrEP era: the French ANRS PRIMO cohort study

Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study

Spatio‐temporal changes in pre‐exposure prophylaxis uptake among MSM in mainland France between 2016 and 2021: a Bayesian small area approach with MSM population estimation

Incidence, risk factors and outcome of multi-drug resistant Acinetobacter baumannii nosocomial infections during an outbreak in a burn unit

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study

Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96‐week, phase 3b, open‐label, switch trial in virologically suppressed people ≥65 years of age

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

Sensitivity of five rapid HIV tests on oral fluid or finger-stick whole blood: a real-time comparison in a healthcare setting

Injectable long acting antiretroviral for HIV treatment and prevention: perspectives of potential users

Hepatitis Rebound after Infection with Yellow Fever Virus

Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients

Suchergebnisse filtern